Which Peptides Can a Telehealth Clinic Prescribe? FDA Rules for 2026

A telehealth clinic can prescribe an FDA-approved peptide medication when an independently licensed clinician determines that it is medically appropriate, the clinician is authorized in the patient’s location, and the encounter meets applicable state standards. Telehealth changes delivery—not FDA approval, scope of practice, prescribing standards, or corporate-practice restrictions.

Which peptides can a telehealth clinic prescribe in 2026?

The clearest category is an FDA-approved peptide or peptide-based prescription product prescribed for a legitimate medical indication. Examples supported by the research include semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, glucagon, dasiglucagon, teriparatide, calcitonin salmon, and bremelanotide.

That does not mean every use of every ingredient is FDA-approved. Approval can depend on the exact product, formulation, route, population, and indication. A clinic should review current FDA labeling before building a program, writing marketing copy, or creating clinical workflows.

A compounded product is a separate category. Compounded drugs do not receive FDA premarket review for safety, effectiveness, or quality. Some compounding may be permitted under federal and state rules, but a compounded formulation should not be described as FDA-approved, a generic version of a branded product, or the same as a commercial product.

At a glance: approved, compoundable, and restricted peptide categories

The category should be determined before a product appears in the website formulary, intake flow, clinician queue, pharmacy workflow, or subscription offer.

Which FDA-approved peptide medications may belong in a telehealth formulary?

The following examples are FDA-approved products or peptide-based medications identified in the research memo. They are not a recommendation to prescribe, and the exact current label controls.

• Semaglutide: Approved products include Ozempic, Rybelsus, Wegovy, and Wegovy HD. Depending on the product, approved-use examples include type 2 diabetes, chronic weight management, and certain cardiovascular or kidney-risk indications.
• Tirzepatide: Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management and also has an FDA-approved obstructive sleep-apnea indication.
• Liraglutide: Victoza and Saxenda are associated with type 2 diabetes and chronic weight-management indications, respectively.
• Dulaglutide: Trulicity is approved for type 2 diabetes and certain cardiovascular-risk reduction indications.
• Exenatide: Byetta and historically Bydureon have been associated with type 2 diabetes. A clinic should verify current commercial availability before designing a program around a product.
• Glucagon: Approved products include Gvoke and Baqsimi, with labeling for emergency treatment of severe hypoglycemia.
• Dasiglucagon: Zegalogue is approved for severe hypoglycemia.
• Teriparatide: Forteo and approved products have osteoporosis-related indications.
• Calcitonin salmon: Miacalcin and other approved products have narrower, label-specific indications.
• Bremelanotide: Vyleesi is approved for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women.

The practical distinction is between an approved ingredient and an approved product. Even when an ingredient is FDA-approved, a clinic must not assume that a different formulation, combination, route, concentration, or population has the same approval status.

For current labeling, use FDA’s labeling repository and verify the product-specific indications, boxed warnings, contraindications, route, population, and other safety information. Prescribing decisions belong to the independently licensed clinician—not the business, platform, marketer, or intake form.

What are the telehealth peptide therapy rules for prescribing?

Telehealth is a delivery method, not a separate drug-approval pathway. A peptide program should be designed around the same clinical and regulatory controls that would apply to comparable in-person care.

At a minimum, the operating model should address:

1. 1Patient location: Confirm where the patient is located during each encounter. The clinician generally needs to satisfy the rules applicable to that location.
2. 2Clinician authorization: Verify licensure, scope of practice, and any supervision or collaboration requirements for the clinician type in each state.
3. 3Clinical evaluation: Support an evaluation sufficient for the clinician to make an independent decision. A questionnaire alone may not satisfy every state’s requirements or the applicable standard of care.
4. 4Medical rationale: Document the diagnosis or clinical rationale, relevant history, risks, alternatives, and follow-up plan.
5. 5Label review: Use current FDA labeling for the exact product. An off-label use requires independent clinical judgment and should not be presented as an FDA-approved indication.
6. 6Continuity and escalation: Create procedures for follow-up, adverse-event handling, referral, and in-person evaluation when remote care is insufficient.
7. 7Marketing separation: Do not let payment, eligibility automation, or advertising language predetermine a clinical outcome.
8. 8Advertising substantiation: Health claims require appropriate support. Avoid guaranteed outcomes, unsupported testimonials, and claims that a product treats serious conditions without competent substantiation.

These controls are part of peptide therapy telehealth compliance, but they do not replace state-specific legal and clinical review.

Can a telehealth clinic prescribe compounded peptides?

A clinic may be able to coordinate prescriptions for a compounded formulation when federal and state requirements are satisfied and an independently licensed clinician determines that compounding is medically appropriate. The formulation remains compounded, not FDA-approved.

Section 503A compounding

Section 503A generally covers traditional pharmacy or physician compounding for an identified individual patient based on a valid prescription. Federal rules restrict compounding products that are essentially copies of commercially available FDA-approved drugs.

For a 503A workflow, the clinic should be prepared to document:

• The patient-specific clinical rationale.
• Why the approved product is not medically appropriate or commercially available, where relevant.
• The pharmacy’s license and state authorization.
• The pharmacy’s current compounding practices.
• Product labeling, storage, recall, and adverse-event processes.

The clinic should not design a routine substitution workflow that treats a compounded formulation as interchangeable with an available FDA-approved product.

Section 503B outsourcing facilities

Section 503B applies to FDA-registered outsourcing facilities and includes different requirements and restrictions. These facilities face limits on compounding products that are essentially copies of FDA-approved drugs and on the bulk substances they may use.

Drug-shortage status can affect certain federal restrictions, but any exception is conditional and does not make a compounded product FDA-approved. Shortage status changes over time, so a clinic should check the current FDA shortage database rather than rely on an old article, pharmacy statement, or prior workflow.

On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the section 503B bulk-drug list. The research memo describes that action as a proposal, with comments due June 29, 2026—not a final determination. Before publication or launch, verify the final status and any later FDA action.

What should a clinic do with restricted or unapproved peptide products?

A clinic should not market unapproved or FDA-restricted peptide substances as patient-treatment offerings. FDA has described safety, impurity, immunogenicity, characterization, and limited-human-safety concerns for certain bulk peptide substances and has placed some in a restricted category.

The safest formulary architecture is to separate:

• FDA-approved finished products.
• Clinically justified off-label uses of FDA-approved products.
• Compounded formulations that pass federal, state, pharmacy, and clinical review.
• Research or unapproved substances that are excluded from patient-treatment promotion.

A product’s availability on a website, laboratory catalog, or “research use only” page does not establish that it is approved for human treatment. FDA warning letters also show why a business should review claims and product representations before launch.

How do state rules affect peptide prescribing through telehealth?

Rules vary by state, clinician type, patient location, ownership structure, consent requirements, and the nature of the evaluation. A national peptide program needs a state-by-state matrix rather than one national assumption.

• California: The Medical Board states that telehealth is a tool of medical practice and that the same standard of care applies as in person. California requires appropriately licensed practitioners for patients located in California, telehealth consent documentation, and compliance with scope-of-practice rules. California also maintains strong corporate-practice-of-medicine principles: nonphysicians may not own or control a business offering patient evaluation, diagnosis, care, or treatment, and clinical decisions must remain with the physician.
• Florida: Materials applying Rule 64B8-9.014 state that prescribing solely from an electronic questionnaire is inadequate. The physician or physician assistant must document an evaluation that includes sufficient history and physical examination, discussion of treatment options and risks and benefits, and contemporaneous records. An asynchronous form should not be the sole basis for a peptide prescription in Florida.
• Massachusetts: The Board of Registration in Medicine approved a permanent telemedicine policy stating that a prior face-to-face encounter is not required before telemedicine care, while preserving the same standard of care as in-person care. Massachusetts law defines telehealth broadly, but that does not authorize inadequate evaluation or questionnaire-only prescribing.
• Arizona: An Arizona Naturopathic Physicians Medical Board page quotes state law requiring a physical examination before prescribing a prescription medication or a previously established doctor-patient relationship, subject to statutory exceptions. A real-time audio-video encounter may satisfy the physical-examination provision in circumstances addressed by the law. Scope-of-practice rules differ by license type.

These examples are not a national rule. They illustrate why the clinic needs counsel and qualified clinical leadership to review each intended state before accepting patients. For broader launch planning, the telehealth-business programs hub provides the relevant program context, while state-specific legal review remains separate.

What should a clinic include in its peptide program checklist?

Use this sequence before publishing a formulary or accepting a program enrollment:

1. Classify every proposed product

Record whether it is an FDA-approved finished product, a compounded formulation, a restricted bulk substance, or an unapproved research product.

2. Match the product to the intended service

For each approved product, record the exact product name, approved indications, population, route, warnings, contraindications, and current label source. Do not use an ingredient-level description as a substitute for product review.

3. Build the state matrix

List patient-location states, clinician licenses, scope of practice, evaluation requirements, telehealth consent, ownership restrictions, supervision rules, and advertising requirements.

4. Audit pharmacy relationships

Verify pharmacy licensing, 503A or 503B status where relevant, lawful ingredient use, shortage-related assumptions, labeling, storage, recalls, and adverse-event reporting.

5. Separate clinical and business authority

The business may own branding, software, scheduling, billing, and administrative workflows. Independent clinicians must retain authority over evaluation, diagnosis, prescribing, treatment decisions, and follow-up.

6. Review marketing and subscriptions

Remove FDA-approval language for compounded products, brand-equivalence language, outcome guarantees, unsupported testimonials, and claims that payment guarantees a prescription. Recurring plans should clearly disclose material terms, obtain express informed consent before billing, and provide a simple way to stop recurring charges under applicable federal requirements.

7. Test the patient journey

Confirm that location verification, clinician review, payment, prescription decisions, pharmacy routing, follow-up, escalation, and cancellation work in the correct order. Payment should not trigger an automatic prescription promise.

MDLaunchr, the brand behind WhiteLabelClinic.com, is one infrastructure option for coordinating the technology, operational, compliance, clinical-network, and fulfillment relationships involved in a telehealth launch. It is not a treating clinician, law firm, regulator, or pharmacy, and infrastructure does not transfer clinical responsibility. See the peptide therapy program to review how that program is set up.

Disclaimer

This article is educational business information, not medical advice, legal advice, pharmacy advice, or a recommendation to prescribe or use any medication. FDA status, shortage status, product labeling, compounding rules, state telehealth requirements, clinician scope of practice, and advertising standards can change. Clinics should obtain advice from qualified healthcare, legal, pharmacy, and regulatory professionals before launching or changing a peptide program. Prescribing decisions belong to independently licensed clinicians.

Related reading: Med Spa Medical Director Requirements: Telehealth Changes in 2026, How an OB-GYN Practice Can Offer Menopause Care Through Telehealth.